The FDA is reconsidering its approach to COVID-19 vaccine approvals for the upcoming season, citing insufficient data on booster effectiveness and declining public trust in vaccination recommendations. FDA Commissioner Dr. Marty Makary emphasizes the need for robust clinical data before endorsing n…